Stevanato Group S.p.A.
Stevanato Group provides drug containment, drug delivery, diagnostic and engineering solutions to pharmaceutical, biotechnology and life sciences companies. Its Biopharmaceutical and Diagnostic Solutions segment includes products, processes and services for containing and delivering drugs and reagents, as well as diagnostic consumables, medical devices and drug delivery systems. Its Engineering segment supplies equipment and technologies for pharmaceutical, biotechnology and diagnostic manufacturing, including visual inspection, device assembly, packaging and glass converting. Products include pharmaceutical containers such as syringes, vials and cartridges, and the EZ-fill® line of ready-to-use drug containers. The company also provides services across drug development, from pre-clinical and clinical stages through commercialization, and after-sales support for machinery. It makes money by selling products and equipment and providing processes and services, primarily through business-to-business channels and selected distributors. Stevanato Group is headquartered in Piombino Dese, Padua, Italy.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $STVN in the last 7 days.
Stevanato Group reported Q3 Non-GAAP EPS of €0.16 and revenue of €326.1M. The company expects low single-digit growth in 2027 due to reduced syringe volumes for a key customer, according to its press release.
FEDERICI WILLIAM J purchased 20,000 shares of Stevanato Group S.p.A. (STVN) at $13.72 ($0.27M total) on 2026-11-09.
MOREL DONALD E JR purchased 25,000 shares of Stevanato Group S.p.A. (STVN) at $13.07 ($0.33M total) on 2026-11-06.
Recent STVN coverage spans financial news, earnings and insider activity.
In the last 30 days, STVN insiders filed 2 SEC Form 4 transactions — 2 purchases ($601K) and no sales. The most active reporter was MOREL DONALD E JR with 1 filing.
Stevanato Group reported Q3 Non-GAAP EPS of €0.16 and revenue of €326.1M. The company expects low single-digit growth in 2027 due to reduced syringe volumes for a key customer, according to its press release.
The insider purchase may signal confidence and could provide modest buying pressure.
Insider purchase may signal confidence, modest upward pressure.
William Blair downgraded Stevanato Group to Market Perform from Outperform. The change in rating may impact investor sentiment and trading activity.
UBS kept Stevanato Group at Neutral but cut its price target to $16 from $23, a 30.4% reduction. This implies a 19.0% upside from the Nov 4 close of $13.44.
AlphAI scores every news story that mentions STVN with an AI model for sentiment and relevance, and aggregates insider trades from Stevanato Group S.p.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stevanato Group reported Q3 Non-GAAP EPS of €0.16 and revenue of €326.1M. The company expects low single-digit growth in 2027 due to reduced syringe volumes for a key customer, according to its press release.
FEDERICI WILLIAM J purchased 20,000 shares of Stevanato Group S.p.A. (STVN) at $13.72 ($0.27M total) on 2026-11-09.
MOREL DONALD E JR purchased 25,000 shares of Stevanato Group S.p.A. (STVN) at $13.07 ($0.33M total) on 2026-11-06.
William Blair downgraded Stevanato Group to Market Perform from Outperform. The change in rating may impact investor sentiment and trading activity.
UBS kept Stevanato Group at Neutral but cut its price target to $16 from $23, a 30.4% reduction. This implies a 19.0% upside from the Nov 4 close of $13.44.
Citigroup kept Stevanato Group at Buy but cut its price target to $20 from $26, a 23.1% reduction. The new target suggests a 48.8% upside from the Nov 4 close of $13.44, according to the bank.
Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) – November 3, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug de
Stevanato Group (STVN) shares dropped 26% after reporting Q3 revenue growth of 8% to 326.1M euros, beating expectations, but providing a cautious 2027 outlook with low single-digit revenue growth. Adjusted EPS was 16 euro cents, in line with estimates. The company's market value fell to $4B. GLP-1 therapy revenue was 17-18% of total revenue, with other biologics growing over 30%. The Engineering segment saw a 12% revenue decline.
Conestoga Capital Advisors highlighted Stevanato Group S.p.A. (STVN) in its Q3 2026 investor letter, noting 8% revenue growth and expanded EBITDA margins in 2Q26. The company's shift to higher-value products, particularly in biologics and GLP-1 therapies, drove margin expansion. STVN's stock closed at $19.64 on October 27, 2026, with a market cap of $5.36 billion, showing a 2.39% YTD decline.
Aptar Pharma (ATR) and Stevanato Group (STVN) are collaborating to evaluate pre-filled syringe configurations for biotech and pharmaceutical companies. They aim to provide system-level data to support earlier evaluation of packaging configurations, focusing on sensitive biologics and injectable therapies. The collaboration combines Aptar Pharma's expertise in elastomeric components with Stevanato Group's expertise in prefillable syringe systems.
